Kun Yun

Kun Yun
Mayo Clinic - Rochester · Department of Molecular Medicine

Master of Science

About

27
Publications
4,272
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
75
Citations
Introduction
Skills and Expertise

Publications

Publications (27)
Article
Our group has reported that transient CD19 antigen masking of leukemic cells with the CD19 monoclonal antibody (mAb), tafasitamab, resulted in reduction of CD19 chimeric antigen receptor T cell (CART19) apoptosis, enhanced CAR T proliferation, improved anti-tumor activity, diminished tumor pyroptosis, and reduced severity of cytokine release syndro...
Article
Full-text available
In the development of various strategies of anti-CD19 immunotherapy for treatment of B-cell malignancies, it remains unclear whether CD19 monoclonal antibody therapy impairs subsequent CD19-targeted chimeric antigen receptor T-cell (CART19) therapy. We evaluated the potential interference between the CD19-targeting monoclonal antibody tafasitamab a...
Preprint
Durable response to chimeric antigen receptor T (CART) cell therapy remains limited in part due to CART cell exhaustion. We investigated the regulation of CART cell exhaustion with three independent approaches including: a genome-wide CRISPR knockout screen using a validated in vitro model for exhaustion, RNA and ATAC sequencing on baseline and chr...
Article
Full-text available
Chimeric antigen receptor T (CAR-T) cell therapy has drawn increasing attention over the last few decades given its remarkable effectiveness and breakthroughs in treating B cell hematological malignancies. Even though CAR-T cell therapy has outstanding clinical successes, most treated patients still relapse after infusion. CARs are derived from the...
Article
CD19 directed chimeric antigen receptor T (CART19) cell therapy has resulted in remarkable outcomes in B cell malignancies and was FDA approved in multiple indications. However, durable remissions are limited to 40% of treated patients. Inhibitory myeloid cells in tumor microenvironment have been found to suppress T cell expansion and contribute to...
Article
While chimeric antigen receptor T-cell therapy targeting CD19 (CART19) has shown remarkable success in the treatment of hematological malignancies, the durable response rates remain approximately 40% and there are limited solutions for CART cell therapy in the treatment of solid tumors. To further understand mechanisms of resistance, including CART...
Article
Glioblastoma multiforme (GBM) is the most aggressive and common form of brain tumor, and it is characterized by an immunosuppressive tumor microenvironment (TME) that supports tumor growth and pathology. An integral part of the GBM stroma is the mesenchymal stem cells (MSC), which promote GBM growth. Receptor tyrosine kinase EphA3, a member of the...
Conference Paper
Full-text available
Background Glioblastoma multiforme (GBM) is the most lethal form of brain cancer with a median survival of < 2 years despite treatment advances. Evidence indicates that GBM has been shown to reprogram immune responses to promote its progression. A predominant component of the immunosuppressive tumor microenvironment (TME) is glioblastoma-associated...
Article
Epstein Barr Virus (EBV) latent infection is associated with multiple types of cancer. Several clinical studies have targeted EBV antigens as immune therapeutic targets with limited efficacy of EBV+ malignancies, suggesting additional targets might be important. BamHI-A rightward frame 1 (BARF1) is an EBV antigen that is highly expressed in EBV-ass...
Article
Full-text available
Epstein Barr Virus (EBV) latent infection is associated with several types of cancer. Several clinical studies have targeted EBV antigens as immune therapeutic targets with limited efficacy of EBV malignancies, suggesting additional targets might be important. BamHI-A rightward frame 1 (BARF1) is an EBV antigen that is highly expressed in EBV⁺ naso...
Article
Introduction: It has become increasingly apparent that chimeric antigen receptor T (CART) cell activation and differentiation level is an important determinant of CART cell fate and response to therapy. In this study, we aimed to 1) measure levels of activation-induced surface death receptors and ligands on CART cells; 2) investigate how CART cell...
Article
Full-text available
More than 100 million people have been infected with SARS-CoV-2. Common laboratory mice are not susceptible to wild-type SARS-CoV-2 infection, challenging the development and testing of effective interventions. Here, we describe the development and testing of a mouse model for SARS-CoV-2 infection based on transduction of the respiratory tract of l...
Article
Hyperammonemia is a dangerous life-threatening metabolic complication characterized by markedly elevated ammonia levels that can lead to irreversible brain damage if not carefully monitored. Current pharmacological treatment strategies available for hyperammonemia patients are suboptimal and associated with major side effects. In this study, we foc...
Article
Full-text available
Arginase is a complex and unique enzyme that plays diverse roles in health and disease. By metabolizing arginine, it can shape the outcome of innate and adaptive immune responses. The immunomodulatory capabilities of arginase could potentially be applied for local immunosuppression or induction of immune tolerance. Using enhanced DNA delivery appro...
Article
Full-text available
The need for a malaria vaccine is indisputable. A single vaccine for Plasmodium pre-erythrocytic stages targeting the major sporozoite antigen circumsporozoite protein (CSP) has had partial success. Additionally, CD8+ T cells targeting liver-stage (LS) antigens induced by live attenuated sporozoite vaccines were associated with protection in human...
Article
Full-text available
The loss of previously adaptive traits is typically linked to relaxation in selection, yet the molecular steps leading to such repeated losses are rarely known. Molecular studies of loss have tended to focus on gene sequences alone, but overlooking other aspects of protein expression might underestimate phenotypic diversity. Insights based almost s...
Preprint
Full-text available
Studies of opsin genes offer insights into the evolutionary history and molecular basis of vertebrate color vision, but most assume intact open reading frames equate to functional phenotypes. Despite known variation in opsin repertoires and associated visual phenotypes, the genetic basis of such patterns has not been examined at each step of the ce...

Questions

Questions (20)
Question
Hi, I did some scRNAseq as well as protein expression analysis on the same sample, however, the RNA level is not consistent with the protein level. How do people usually explain this piece of data in manuscripts? Thanks!
Question
Hi, I'm using a very hydrophobic peptide for tetramer staining. The peptide can only be dissolved in DMSO, and then further diluted by PBS or water. I have tried 10, 5, 3 and 2 mg/mL as the stock concentration, and only when it's dissolved at 2 mg/mL in DMSO, it can be further diluted in PBS or water without any aggregation.
However, for tetramer staining, it's suggested to not exceed the final concentration of 10% DMSO in the peptide exchange reaction for tetramer assembly, but in my case, the 2 mg/mL peptide stock leads to a 16% DMSO in the exchange reaction. Does anyone have any experience to somehow lower the DMSO concentration in the reaction? Like add more monomers or add more PBS to the reaction to increase the final volume?
Thanks!
Question
Hi, I have been trying to dissolve a very hydrophobic peptide (containing cysteine) with DMF, however, the solution looks very cloudy when I add DMF, and further dilutions with water doesn't help much. Does anyone have any tips on this issue? In addition, I'm use NanoDrop to measure concentration, but when I use DMF as blank, it shows "bad blank". By the way, I'm measuring the concentration at A280. Thanks!
Question
Hi, I'm trying to block FcR on human macrophages in some in vitro cocultures with human T cells. Is there any FcR blocking reagents used in vitro culture?
Thanks,
Kun
Question
Hi,
I have a basic question about cell engineering. Is it possible to load or engineer mammalian cells to produce certain chemicals?
Question
Hi,
How long do you usually rest cryopreserved dendritic cells after thawing? And what cell culture media does it need for resting? Thanks!
Question
Hi,
Has anybody ever seen stained cell population moves downwards compared to FMO?
Question
Hi,
I'm trying to stimulate human T cells with magnetic beads coated with antibodies. I have streptavidin-coated beads as well as biotinylated antibodies. According to the vendor, they usually incubate cells with antibodies first and then mix them with beads. I'm wondering if it's feasible to immobilize the antibodies onto beads first and then add to cells. Thanks!
Question
Hi,
I'm planning to electroporate mature dendritic cells with in vitro transcribed mRNA, but I'm not sure how people usually decide the dose of mRNA and number of mDC to reach a good transfection efficiency (80-90% positivity). Does the total amount of RNA or the concentration of RNA matter? Thanks!
Kun
Question
Hi,
I have been using HighScribe T7 polymerase kit for in vitro transcription from NEB, but the protocol gives a 20uL reaction with 1ug DNA template, which is not enough for my downstream experiments. Does anybody know if I can just proportionally scale up all the reagents or do I have to divide into multiple 20uL reactions to reach the amount of RNA I need? Thanks!
Kun
Question
Hi, does anyone know how to find the DNA sequence encoding the scFv region of a specific antibody? Is there a library for these? Thanks!
Question
Hi, I'm using neutralizing monoclonal antibody to neutralize cytokine in cell culture. I added neutralizing antibody on Day 0, and measured the cytokine level 3 days later, but it seems that the cytokine level is still high. Is it possible that the neutralizing antibody is degraded in cell culture within 3 days? Thank you!
Question
I read papers about in vitro transcribed RNA. What is the difference between in vitro transcribed RNA and commercially purchased RNA?
Thanks
Question
I am trying to expand CTLs in vitro and have noticed that many studies usually use irradiated PBMCs as feeder cells besides supplement with cytokines. What ratio of CTL to PBMCs does it usually require to reach a decent level of proliferation?
Thanks!
Question
Hi,
I'm activating CD8 T cells by adding MHC-I restricted epitopes to whole PBMCs in vitro according to previous published studies. I noticed that cell feeding occurs 24 hrs after adding peptides and the feeding procedure involves resuspending cells by pipetting gently. Does this disrupt the interactions between DC and CD8 T cells and negatively affect T cell activation? Thanks!

Network

Cited By